Mooren's ulcer

Last updated

Mooren's ulcer is a rare idiopathic ocular disorder that may lead to blindness due to progressive destruction of the peripheral cornea. Although the etiology of Mooren's ulcer is poorly understood, recent evidence suggests that the pathogenesis of this disease appears to be the result of an autoimmune process directed against molecules expressed in the corneal stroma. [1]

Contents

Mooren's ulcer is also defined as a special and the most common type of peripheral ulcerative keratitis (PUK).

Signs and symptoms

Symptoms of Mooren's ulcer can include: [1]

Some epidemiological studies have noted that men tend to be affected more than women. [2] [3]

Classification

The most commonly used classification was proposed by Watson in 1997. He divided the disease into three types based on the clinical picture: [4]

Risk factors

Several risk factors affecting the development of Mooren's ulcer have been suggested.[ citation needed ]

Corneal trauma

Previous ocular trauma or infection can cause disruption of the corneal integrity resulting in the expression of tissue-specific antigens that are normally hidden from the immune system. It may lead to an increased risk of a sensitization to corneal antigens and an autoimmune reaction against antigens expressed in corneal tissues.

HLA association

Like most autoimmune diseases, Mooren's ulcer is thought to be associated with specific HLA haplotypes. In some studies, HLA-DR17 and HLA-DQ2 have been found in increased frequencies in affected patients compared to healthy controls. These results propose a possible association between HLA and Mooren's ulcer. [5]

Pathology

The precise pathophysiological mechanism of Mooren's ulcer remains unclear, but most data suggest that both cell-mediated immunity and humoral immunity are involved in the pathogenesis of the disease. [6]

Reduces numbers of suppressor T cells have been found in peripheral blood from patients with Mooren's ulcer. This deficit in systematic immunoregulatory mechanism may lead to loss of a control over autoreactive T and B cells and contributes to disease pathogenesis. [7]

Immunohistochemical studies in patients suffered from Mooren's ulcer showed massive infiltration of multiple types of inflammatory cells in the conjunctival tissue.

The cell types in the inflammatory lesion includes CD4+ and CD8+ T-lymphocytes, B-lymphocytes, macrophages, a small amount of neutrophils was also observed in the conjunctiva from patients with Mooren's ulcer. [6] [8] [9]

In addition, circulating IgG antibodies with specificity for corneal and conjunctival antigens have been isolated from patients with Mooren’s ulcer. [10] Gottsch and colleagues have suggested that calgranulin C, a protein expressed in the corneal stroma, may be a possible main target for autoimmune response causing Mooren’s ulcer. [11]

Also, significantly increased expression levels of adhesion and co-stimulatory molecules have been found in ocular tissues affected by Mooren's ulcer compared to healthy eyes. Upregulation of adhesion molecules allows leukocyte migration into inflamed tissues. Co-stimulatory molecules may contribute to sustained local immune activation. Therefore, blockage of these molecules suppose to be a protentional therapeutic strategy for suppressing the inflammatory progression. [9]

Elevated levels of proteases and collagenases which damage the corneal stroma have also been found in affected conjunctival tissues. [12]

Diagnosis

In view of rarity and limited knowledge of the etiology of Mooren’s ulcer, the diagnosis of the disease is complicated. The absence of any systematic disorders which can lead to peripheral corneal ulceration supports the diagnosis of Mooren’s ulcer. To diagnose Mooren’s ulcer, it is necessary to rule out other forms of non-infectious peripheral ulcerative keratitis. [3]

Treatment

Medical treatment

Topical corticosteroids are usually used as first line of therapy. Severe cases require administration of systemic immunosuppressive agents. The more commonly used drugs are cyclosporine A, methotrexate and cyclophosphamide.

Several case reports showed that biological agents, such as anti-tumor necrosis factor alpha (anti-TNF) or monoclonal antibodies against CD20, also can be used as an effective treatment of progressive Mooren’s ulceration. [13] [14]

Surgical treatment

If patients do not respond to medication, surgical intervention must be performed. Conjunctival excision has been shown to be an effective method. The principle of this surgery is based on the removal of unhealthy limbal conjunctiva adjacent to the ulcer. slow down the disease progression due to eliminating the local source of inflammatory cells, mediators and enzymes which cause the tissue damage. [15]

Another surgical treatment option which has been successfully used as a treatment for Mooren’s ulcer is Amniotic Membrane Transplantation (AMT). This method consists of applying a piece of amniotic membrane to the ocular surface. Amniotic membrane patches are prepared from placental tissues from women who had a planned cesarean sections. AMT appears to be a useful therapy which results with stabilization of the ulcer progression and corneal epithelial defect healing. [16] It is most likely, that amniotic membrane used as an ocular graft stop the inflammation process because of the expression of immunoregulatory molecules, including Fas ligand and HLA–G antigens. In addition, the amniotic membrane contains a large number of collagens, growth factors and protease inhibitors which can promote healing and reconstruction of the conjunctival epithelium. [17]

Other surgical interventions such as lamellar keratectomy, keratoepithelioplasty and corneal transplantation have also been reported as effective treatment options for Mooren’s ulcer.

Related Research Articles

<span class="mw-page-title-main">Cornea</span> Transparent front layer of the eye

The cornea is the transparent front part of the eye that covers the iris, pupil, and anterior chamber. Along with the anterior chamber and lens, the cornea refracts light, accounting for approximately two-thirds of the eye's total optical power. In humans, the refractive power of the cornea is approximately 43 dioptres. The cornea can be reshaped by surgical procedures such as LASIK.

<span class="mw-page-title-main">Pterygium (eye)</span> Pinkish, triangular tissue growth on the cornea of the eye

A pterygium of the eye is a pinkish, roughly triangular tissue growth of the conjunctiva onto the cornea of the eye. It typically starts on the cornea near the nose. It may slowly grow but rarely grows so large that it covers the pupil and impairs vision. Often both eyes are involved.

<span class="mw-page-title-main">Conjunctiva</span> Part of the eye; protective outer layer covering the sclera

In the anatomy of the eye, the conjunctiva is a thin mucous membrane that lines the inside of the eyelids and covers the sclera. It is composed of non-keratinized, stratified squamous epithelium with goblet cells, stratified columnar epithelium and stratified cuboidal epithelium. The conjunctiva is highly vascularised, with many microvessels easily accessible for imaging studies.

<span class="mw-page-title-main">Red eye (medicine)</span> Eye that appears red due to illness or injury

A red eye is an eye that appears red due to illness or injury. It is usually injection and prominence of the superficial blood vessels of the conjunctiva, which may be caused by disorders of these or adjacent structures. Conjunctivitis and subconjunctival hemorrhage are two of the less serious but more common causes.

A topical anesthetic is a local anesthetic that is used to numb the surface of a body part. They can be used to numb any area of the skin as well as the front of the eyeball, the inside of the nose, ear or throat, the anus and the genital area. Topical anesthetics are available in creams, ointments, aerosols, sprays, lotions, and jellies. Examples include benzocaine, butamben, dibucaine, lidocaine, oxybuprocaine, pramoxine, proxymetacaine (proparacaine), and tetracaine.

<span class="mw-page-title-main">Corneal ulcers in animals</span> Veterinary inflammatory condition of the cornea

A corneal ulcer, or ulcerative keratitis, is an inflammatory condition of the cornea involving loss of its outer layer. It is very common in dogs and is sometimes seen in cats. In veterinary medicine, the term corneal ulcer is a generic name for any condition involving the loss of the outer layer of the cornea, and as such is used to describe conditions with both inflammatory and traumatic causes.

<span class="mw-page-title-main">Vernal keratoconjunctivitis</span> Medical condition

Vernal keratoconjunctivitis is a recurrent, bilateral, and self-limiting type of conjunctivitis having a periodic seasonal incidence.

<span class="mw-page-title-main">Corneal neovascularization</span> Medical condition

Corneal neovascularization (CNV) is the in-growth of new blood vessels from the pericorneal plexus into avascular corneal tissue as a result of oxygen deprivation. Maintaining avascularity of the corneal stroma is an important aspect of healthy corneal physiology as it is required for corneal transparency and optimal vision. A decrease in corneal transparency causes visual acuity deterioration. Corneal tissue is avascular in nature and the presence of vascularization, which can be deep or superficial, is always pathologically related.

<span class="mw-page-title-main">Corneal ulcer</span> Medical condition of the eye

Corneal ulcer, also called keratitis, is an inflammatory or, more seriously, infective condition of the cornea involving disruption of its epithelial layer with involvement of the corneal stroma. It is a common condition in humans particularly in the tropics and in farming. In developing countries, children afflicted by vitamin A deficiency are at high risk for corneal ulcer and may become blind in both eyes persisting throughout life. In ophthalmology, a corneal ulcer usually refers to having an infection, while the term corneal abrasion refers more to a scratch injury.

<span class="mw-page-title-main">Corneal tattooing</span> Tattoo located on the cornea of the bearers eye

Corneal tattooing is the practice of tattooing the cornea of the human eye. Reasons for this practice include improvement of cosmetic appearance and the improvement of sight. Many different methods and procedures exist today, and there are varying opinions concerning the safety or success of this practice.

<span class="mw-page-title-main">Symblepharon</span> Medical condition

A symblepharon is a partial or complete adhesion of the palpebral conjunctiva of the eyelid to the bulbar conjunctiva of the eyeball. It results either from disease or trauma. Cicatricial pemphigoid and, in severe cases, rosacea may cause symblepharon. It is rarely congenital. Its treatment is symblepharectomy.

<span class="mw-page-title-main">Conjunctivochalasis</span> Medical condition

Conjunctivochalasis, also known as mechanical dry eye (MDE), is a common eye surface condition characterized by the presence of excess folds of the conjunctiva located between the globe of the eye and the eyelid margin.

<span class="mw-page-title-main">Herpes simplex keratitis</span> Medical condition

Herpetic simplex keratitis is a form of keratitis caused by recurrent herpes simplex virus (HSV) infection in the cornea.

Jeewan Singh Titiyal is an Indian ophthalmologist, credited with the first live cornea transplant surgery by an Indian doctor. He was honoured by the Government of India, in 2014, by bestowing on him the Padma Shri, the fourth highest civilian award, for his services to the field of medicine.

<span class="mw-page-title-main">Limbal stem cell</span>

Limbal stem cells, also known as corneal epithelial stem cells, are unipotent stem cells located in the basal epithelial layer of the corneal limbus. They form the border between the cornea and the sclera. Characteristics of limbal stem cells include a slow turnover rate, high proliferative potential, clonogenicity, expression of stem cell markers, as well as the ability to regenerate the entire corneal epithelium. Limbal stem cell proliferation has the role of maintaining the cornea; for example, by replacing cells that are lost via tears. Additionally, these cells also prevent the conjunctival epithelial cells from migrating onto the surface of the cornea.

Neurotrophic keratitis (NK) is a degenerative disease of the cornea caused by damage of the trigeminal nerve, which results in impairment of corneal sensitivity, spontaneous corneal epithelium breakdown, poor corneal healing and development of corneal ulceration, melting and perforation. This is because, in addition to the primary sensory role, the nerve also plays a role maintaining the integrity of the cornea by supplying it with trophic factors and regulating tissue metabolism.

<span class="mw-page-title-main">V. S. Sangwan</span> Indian ophthalmologist

Virender Singh Sangwan is an Indian ophthalmologist and the Dr. Paul Dubord Chair professor and director of the L. V. Prasad Eye Institute, Hyderabad. Known for his research on limbal stem cells, Sangwan is the founder secretary and an adviser of the Uveitis Society of India. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Medical Sciences in 2006.

<span class="mw-page-title-main">Corneal opacity</span> Medical condition

Corneal opacification is a term used when the human cornea loses its transparency. The term corneal opacity is used particularly for the loss of transparency of cornea due to scarring. Transparency of the cornea is dependent on the uniform diameter and the regular spacing and arrangement of the collagen fibrils within the stroma. Alterations in the spacing of collagen fibrils in a variety of conditions including corneal edema, scars, and macular corneal dystrophy is clinically manifested as corneal opacity. The term corneal blindness is commonly used to describe blindness due to corneal opacity.

Exposure keratopathy is medical condition affecting the cornea of eyes. It can lead to corneal ulceration and permanent loss of vision due to corneal opacity.

Peripheral Ulcerative Keratitis (PUK) is a group of destructive inflammatory diseases involving the peripheral cornea in human eyes. The symptoms of PUK include pain, redness of the eyeball, photophobia, and decreased vision accompanied by distinctive signs of crescent-shaped damage of the cornea. The causes of this disease are broad, ranging from injuries, contamination of contact lenses, to association with other systemic conditions. PUK is associated with different ocular and systemic diseases. Mooren's ulcer is a common form of PUK. The majority of PUK is mediated by local or systemic immunological processes, which can lead to inflammation and eventually tissue damage. Standard PUK diagnostic test involves reviewing the medical history and a completing physical examinations. Two major treatments are the use of medications such as corticosteroids or other immunosuppressive agents and surgical resection of the conjunctiva. The prognosis of PUK is unclear with one study providing potential complications. PUK is a rare condition with an estimated incidence of 3 per million annually.

References

  1. 1 2 Zelefsky, Joseph R; Srinivasan, Muthiah; Cunningham, Emmett T (August 2011). "Mooren's ulcer". Expert Review of Ophthalmology. 6 (4): 461–467. doi:10.1586/eop.11.46. ISSN   1746-9899. S2CID   29415711.
  2. ↑ Dong, Yanling; Zhang, Yangyang; Xie, Lixin; Ren, Jianmei (February 2017). "Risk Factors, Clinical Features, and Treatment Outcomes of Recurrent Mooren Ulcers in China". Cornea. 36 (2): 202–209. doi:10.1097/ico.0000000000001084. ISSN   0277-3740. PMID   28060068. S2CID   13508732.
  3. 1 2 Srinivasan, M.; Zegans, M. E; Zelefsky, J. R; Kundu, A.; Lietman, T.; Whitcher, J. P; Cunningham, E. T (2006-10-11). "Clinical characteristics of Mooren's ulcer in South India". British Journal of Ophthalmology. 91 (5): 570–575. doi:10.1136/bjo.2006.105452. ISSN   0007-1161. PMC   1954782 . PMID   17035269.
  4. ↑ Watson, P G (May 1997). "Management of Mooren's ulceration". Eye. 11 (3): 349–356. doi: 10.1038/eye.1997.74 . ISSN   0950-222X. PMID   9373475. S2CID   12163492.
  5. ↑ Taylor, Craig J.; Smith, Sheila I.; Morgan, Catherine H.; Stephenson, Susan F.; Key, Tim; Srinivasan, M.; Cunningham, Emmett; Watson, Peter G. (2000-01-01). "HLA and Mooren's ulceration". British Journal of Ophthalmology. 84 (1): 72–75. doi:10.1136/bjo.84.1.72. ISSN   0007-1161. PMC   1723219 . PMID   10611103.
  6. 1 2 Lee, Hyun Ju; Kim, Mee Kum; Wee, Won Ryang; Oh, Joo Youn (September 2015). "Interplay of Immune Cells in Mooren Ulcer". Cornea. 34 (9): 1164–1167. doi:10.1097/ICO.0000000000000471. ISSN   0277-3740. PMID   25970436. S2CID   30578961.
  7. ↑ Murray, P. I.; Rahi, A. H. (March 1984). "Pathogenesis of Mooren's ulcer: some new concepts". The British Journal of Ophthalmology. 68 (3): 182–187. doi:10.1136/bjo.68.3.182. ISSN   0007-1161. PMC   1040283 . PMID   6230102.
  8. ↑ Shinomiya, Katsuhiko; Ueta, Mayumi; Sotozono, Chie; Inatomi, Tsutomu; Yokoi, Norihiko; Koizumi, Noriko; Kinoshita, Shigeru (2013-03-01). "Immunohistochemical analysis of inflammatory limbal conjunctiva adjacent to Mooren's ulcer". British Journal of Ophthalmology. 97 (3): 362–366. doi:10.1136/bjophthalmol-2012-302631. ISSN   0007-1161. PMID   23292924. S2CID   7491218.
  9. 1 2 Kafkala, Chrysanthi; Choi, John; Zafirakis, Panayotis; Baltatzis, Stefanos; Livir-Rallatos, Charalampos; Rojas, Blanca; Foster, C. Stephen (July 2006). "Mooren Ulcer: An Immunopathologic Study". Cornea. 25 (6): 667–673. doi:10.1097/01.ico.0000214216.75496.7e. ISSN   0277-3740. PMID   17077658. S2CID   1948763.
  10. ↑ Gottsch, John D.; Liu, Sammy H.; Stark, Walter J. (April 1992). "Mooren's Ulcer and Evidence of Stromal Graft Rejection After Penetrating Keratoplasty". American Journal of Ophthalmology. 113 (4): 412–417. doi: 10.1016/s0002-9394(14)76164-1 . ISSN   0002-9394. PMID   1558115.
  11. ↑ Gottsch, J. D.; Li, Q.; Ashraf, F.; O'Brien, T. P.; Stark, W. J.; Liu, S. H. (1999-04-01). "Cytokine-Induced Calgranulin C Expression in Keratocytes". Clinical Immunology. 91 (1): 34–40. doi: 10.1006/clim.1998.4681 . ISSN   1521-6616. PMID   10219252.
  12. ↑ Brown, S. I. (1975-11-01). "Mooren's ulcer. Histopathology and proteolytic enzymes of adjacent conjunctiva". British Journal of Ophthalmology. 59 (11): 670–674. doi:10.1136/bjo.59.11.670. ISSN   0007-1161. PMC   1017431 . PMID   173387.
  13. ↑ Xia, Annie; Dietrich-Ntoukas, Tina; Pleyer, Uwe (2022-01-20). "Effect of Anti-TNF Treatment on Mooren's Ulcer: A Case Series and Review of the Literature". Ocular Immunology and Inflammation: 1–7. doi:10.1080/09273948.2021.2023581. ISSN   0927-3948. PMID   35050832. S2CID   246164471.
  14. ↑ Guindolet, Damien; Reynaud, Clotilde; Clavel, Gaelle; Belangé, Georges; Benmahmed, Maycene; Doan, Serge; Hayem, Gilles; Cochereau, Isabelle; Gabison, Eric E (2016-07-22). "Management of severe and refractory Mooren's ulcers with rituximab". British Journal of Ophthalmology. 101 (4): 418–422. doi:10.1136/bjophthalmol-2016-308838. ISSN   0007-1161. PMID   27450147. S2CID   206875244.
  15. ↑ Kalogeropoulos, Christos D.; Malamou–Mitsi, Vassiliki D.; Aspiotis, Miltiadis B.; Psilas, Konstantinos G. (2004-01-01). "Bilateral Mooren's Ulcer in Six Patients: Diagnosis, Surgery and Histopathology". International Ophthalmology. 25 (1): 1–8. doi:10.1023/B:INTE.0000018510.06715.c9. ISSN   1573-2630. PMID   15085968. S2CID   24410012.
  16. ↑ Ngan, Nguyen D; Chau, Hoang TM (July 2011). "Amniotic membrane transplantation for Mooren's ulcer: Amniotic membrane for Mooren's ulcer". Clinical & Experimental Ophthalmology. 39 (5): 386–392. doi:10.1111/j.1442-9071.2010.02479.x. PMID   21176038. S2CID   43523619.
  17. ↑ Kubo, Masato; Sonoda, Yasushi; Muramatsu, Ryuji; Usui, Masahiko (2001-06-01). "Immunogenicity of Human Amniotic Membrane in Experimental Xenotransplantation". Investigative Ophthalmology & Visual Science. 42 (7): 1539–1546. ISSN   1552-5783. PMID   11381058.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.